Combination treatment for stomach cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs — an immunotherapy (sintilimab), a targeted therapy (bevacizumab), and chemotherapy — for a specific type of stomach cancer that produces high AFP and has spread to the liver. The goal is to see if this treatment can shrink tumors enough to make them removable by surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have stomach cancer or cancer where the stomach meets the esophagus, and it has spread to the liver (type 1 liver metastasis)
- Your blood test shows a high level of alpha-fetoprotein (AFP) or your tumor stains positive for AFP
- You are in fairly good health (able to do light activity) and expected to live at least 3 months
- You have not had prior chemotherapy, radiation, or surgery for this cancer
- Your cancer is HER2-negative and has not spread to other organs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial compares three different treatment combinations for advanced stomach cancer that hasn't spread to the brain and is HER2-negative. It includes an immunotherapy drug (sintilimab) with different chemotherapy backbones, and one option adds a targeted therapy (lenvatinib). The goal is to see which combination works best and has acceptable side effects.
This trial tests a combination of two drugs (liposomal irinotecan and sintilimab) for people with stomach or gastroesophageal junction cancer that has progressed after at least one round of standard chemotherapy. The goal is to see if this combo can help shrink tumors or slow the cancer's growth.
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of two immunotherapy drugs (ipilimumab and sintilimab) with chemotherapy (modified XELOX) as a first treatment for stomach cancer that cannot be removed by surgery. The goal is to see if this combination can shrink the tumor enough to allow surgery later.
Hear when a new AFP Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.